ARKGARK Genomic Revolution ETF

Grow my money11y track recordRanked #690 of 2,960 in this goal

Seeks long-term growth of capital.

By ARK ETF Trust · Launched 2014

Annual Cost

0.75%

#3,765 of 5,562 · expensive

Fund Size

$1.3B

#966 of 5,562 · large

Return (1Y)Goal

+55.7%

Track Record

11 years

#1,238 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$16,282+62.8%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

What it actually holds

By weight

Concentration

Top 10 holdings = 58.4% of fundmoderately concentrated

Tempus AI Inc

8.3%

CRISPR Therapeutics AG

8.0%

Twist Bioscience Corp

7.2%

Personalis Inc

6.1%

Guardant Health Inc

6.0%

10X Genomics Inc

5.2%

Beam Therapeutics Inc

4.8%

Illumina Inc

4.5%

Natera Inc

4.3%

Recursion Pharmaceuticals Inc

4.0%

Asset allocation

Stocks

99.8%

Cash

0.2%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

42.6%High

Year-on-year price swings

Max drawdown

-83.6%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.17Below average

Sortino (3Y)

0.25Moderate downside risk

Where to buy

Listing

Exchange: Cboe BZX

Full fund details

Objective: Seeks long-term growth of capital.
Strategy: Invests primarily in equity securities of companies across various sectors relevant to the genomics revolution. Actively selects firms focused on genomic innovations, including healthcare and biotechnology, leveraging thematic research to identify disruptive trends.
Inception date: October 31, 2014
Fund family: ARK ETF Trust